Nathalie Lalevée

Dr. Nathalie Lalevée

Center for CardioVascular and Nutrition Research, Marseille 05, France
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2017 in Circulation
Verified
Journal Article
Closed access
PDF file
MEMarion Escudier
Marion Escudier
JCJennifer Cautela
Jennifer Cautela
NMNausicaa Malissen
Nausicaa Malissen
YAYann Ancedy
Yann Ancedy
MOMorgane Orabona
Morgane Orabona
FTFranck Thuny
Franck Thuny

1 March 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
PMPascal Mariot
Pascal Mariot
KVKarine Vanoverberghe
Karine Vanoverberghe
NLNathalie Lalevée
Nathalie Lalevée
MRMichel F. Rossier
Michel F. Rossier
Natalia PrevarskayaNatalia Prevarskaya
Natalia Prevarskaya
Neuroendocrine differentiation of prostate epithelial cells is usually associated with an increased aggressivity and invasiveness of prostate tumors and a poor prognosis. However, the molecular mechanisms involved in this process remain poorly understood. We have investigated the possible expression of voltage-gated calcium channels in human prostate cancer epithelial LNCaP cells and their modulation during neuroendocrine differentiation. A small proportion of undifferentiated LNCaP cells displayed a voltage-dependent calcium current. This proportion and the calcium current density were significantly increased during neuroendocrine differentiation induced by long-term treatments with cyclic AMP permeant analogs or with a steroid-reduced culture medium. Biophysical and pharmacological properties of this calcium current suggest that it is carried by low-voltage activated T-type calcium channels. Reverse transcriptase-PCR experiments demonstrated that only a single type of LVA calcium channel mRNA, an α1H calcium channel mRNA, is expressed in LNCaP cells. Quantitative real-time reverse transcriptase-PCR revealed that α1H mRNA was overexpressed during neuroendocrine differentiation. Finally, we show that this calcium channel promotes basal calcium entry at resting membrane potential and may facilitate neurite lengthening. This voltage-dependent calcium channel could be involved in the stimulation of mitogenic factor secretion and could therefore be a target for future therapeutic strategies.

1 August 2006 in Current Biology
Verified
Journal Article
Closed access
NLNathalie Lalevée
Nathalie Lalevée
BMBruno Monier
Bruno Monier
SSSébastien Sénatore
Sébastien Sénatore
LPLaurent Perrin
Laurent Perrin
MSMichel Sémériva
Michel Sémériva

17 August 2004 in Circulation
Verified
Journal Article
Closed access
PDF file
EPEmeline Perrier
Emeline Perrier
BKBenoît-Gilles Kerfant
Benoît-Gilles Kerfant
NLNathalie Lalevée
Nathalie Lalevée
PBPatrice Bideaux
Patrice Bideaux
MRMichel F. Rossier
Michel F. Rossier
Jean-Pierre BenitahJean-Pierre Benitah
Jean-Pierre Benitah
Background— Cardiac hypertrophy underlies arrhythmias and sudden death, for which mineralocorticoid receptor (MR) activity has recently been implicated. We sought to establish the sequence of ionic events that link the initiating insult and MR to hypertrophy development. Methods and Results— Using whole-cell, patch-clamp and quantitative reverse transcription–polymerase chain reaction techniques on right ventricular myocytes of a myocardial infarction (MI) rat model, we examined the cellular response over time. One week after MI, no sign of cellular hypertrophy was found, but action potential duration (APD) was lengthened. Both an increase in Ca 2+ current ( I Ca ) and a decrease in K + transient outward current ( I to ) underlay this effect. Consistently, the relative expression of mRNA coding for the Ca 2+ channel α1C subunit (Ca v 1.2) increased, and that of the K + channel K v 4.2 subunit decreased. Three weeks after MI, AP prolongation endured, whereas cellular hypertrophy developed. I Ca density, Ca v 1.2, and K v 4.2 mRNA levels regained control levels, but I to density remained reduced. Long-term treatment with RU28318, an MR antagonist, prevented this electrical remodeling. In a different etiologic model of abdominal aortic constriction, we confirmed that APD prolongation and modifications of ionic currents precede cellular hypertrophy. Conclusions— Electrical remodeling, which is triggered at least in part by MR activation, is an initial, early cellular response to hypertrophic insults.

14 March 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
ILInes Lakbar
Ines Lakbar
Sharon EinavSharon Einav
Sharon Einav
NLNathalie Lalevée
Nathalie Lalevée
Ignacio Martin-LoechesIgnacio Martin-Loeches
Ignacio Martin-Loeches
BPBruno Pastene
Bruno Pastene
MLMarc Leone
Marc Leone
Sex and gender dimorphisms are found in a large variety of diseases, including sepsis and septic shock which are more prevalent in men than in women. Animal models show that the host response to pathogens differs in females and males. This difference is partially explained by sex polarization of the intracellular pathways responding to pathogen–cell receptor interactions. Sex hormones seem to be responsible for this polarization, although other factors, such as chromosomal effects, have yet to be investigated. In brief, females are less susceptible to sepsis and seem to recover more effectively than males. Clinical observations produce more nuanced findings, but men consistently have a higher incidence of sepsis, and some reports also claim higher mortality rates. However, variables other than hormonal differences complicate the interaction between sex and sepsis, including comorbidities as well as social and cultural differences between men and women. Conflicting data have also been reported regarding sepsis-attributable mortality rates among pregnant women, compared with non-pregnant females. We believe that unraveling sex differences in the host response to sepsis and its treatment could be the first step in personalized, phenotype-based management of patients with sepsis and septic shock.

8 December 2020 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
JCJennifer Cautela
Jennifer Cautela
SZSarah Zeriouh
Sarah Zeriouh
MGMelanie Gaubert
Melanie Gaubert
LBLaurent Bonello
Laurent Bonello
MLMarc Laine
Marc Laine
FTFranck Thuny
Franck Thuny
Background Myocarditis is a rare but life-threatening adverse event of cancer treatments with immune checkpoint inhibitors (ICIs). Recent guidelines recommend the use of high doses of corticosteroids as a first-line treatment, followed by intensified immunosuppressive therapy (IIST) in the case of unfavorable evolution. However, this strategy is empirical, and no studies have specifically addressed this issue. Therefore, we aimed to investigate and compare the clinical course, management and outcome of ICI-induced myocarditis patients requiring or not requiring IIST. Methods This case–control study included all patients consecutively admitted to The Mediterranean University Center of Cardio-Oncology (Aix-Marseille University, France) for the diagnosis of ICI-induced myocarditis according to Bonaca’s criteria and treated with or without IIST. In addition, we searched PubMed and included patients from previously published case reports treated with IIST in the analysis. The clinical, biological, imaging, treatment, all-cause death and cardiovascular death data of patients who required IIST were compared with those of patients who did not. Results A total of 60 patients (69±12 years) were included (36 were treated with IIST and 24 were not). Patients requiring IIST were more likely to have received a combination of ICIs (39% vs 8%, p=0.01), and developed the first symptoms/signs of myocarditis earlier after the onset of ICI therapy (median, 18 days vs 60 days, p=0.002). They had a significantly higher prevalence of sustained ventricular arrhythmia, complete atrioventricular block, cardiogenic shock and troponin elevation. Moreover, they were more likely to have other immune-related adverse events simultaneously (p<0.0001), especially myositis (p=0.0002) and myasthenia gravis (p=0.009). Patients who required IIST were more likely to die from any cause (50% vs 21%, p=0.02). Among them, patients who received infliximab were more likely to die from cardiovascular causes (OR, 12.0; 95% CI 2.1 to 67.1; p=0.005). Conclusion The need for IIST was more common in patients who developed myocarditis very early after the start of ICI therapy, as well as when hemodynamic/electrical instability or neuromuscular adverse events occurred. Treatment with infliximab might be associated with an increased risk of cardiovascular death.